

N.B. The English text is an in-house translation

The board of directors' of Swedish Orphan Biovitrum AB (publ) statement in accordance with Chapter 19, Section 24 of the Swedish Companies Act

In view of the board of directors' proposal on an authorization for the board of directors to resolve on a directed offer to acquire all of the company's issued series C shares, the board of directors hereby makes the following statement in accordance with Chapter 19, Section 24, the first paragraph, third item, of the Swedish Companies Act.

Subsequent to the presentation of the annual report for the financial year 2010, no other events of material significance to the Company's financial position has occurred than those stated in the interim report for the period 1 January 2011 – 31 March 2011 and the attached press releases issued thereafter.

Apart from the increase in the company's share capital through the share issue registered on 8 June 2011, whereby the share capital was increased by approximately SEK 29,105,800, the Company's restricted equity has not been subject to any changes subsequent to 31 December 2010.

Stockholm, 29 June 2011
Swedish Orphan Biovitrum AB (publ)
the Board of Directors